Breast cancer and cardiovascular outcomes after breast cancer in survivors of Hodgkin lymphoma.
Inge M KrulNaomi B BoekelIris KramerCécile P M JanusAugustinus D G KrolMarten R NijzielJosée M ZijlstraRichard W M van der MaazenJudith M RoesinkJudy N JacobseMichael SchaapveldMarjanka K SchmidtAnnemieke W J Opstal-van WindenGabe S SonkeNicola S RussellBerthe M P AlemanFlora E van LeeuwenPublished in: Cancer (2022)
Patients with breast cancer after Hodgkin lymphoma (BC-HL) may have limited options for BC treatment, due to earlier HL treatment and an associated increased risk of cardiovascular disease (CVD). BC treatment considerations were reported for 71% of BC-HL patients. We examined whether BC-HL patients have a higher risk of CVD or BC events (recurrences/metastases) compared to patients with breast cancer that had no earlier tumors (BC-1). We observed a higher burden of CVD and worse BC outcomes in HL patients compared to BC-1 patients. Clinicians should be aware of increased CVD risk when selecting BC treatment for HL survivors.